Other
May 2025Synthego filed Chapter 11 and launched a strategic restructuring to reduce debt, secure debtor-in-possession financing, and sell its assets to Perceptive Advisors while continuing operations.
SourceCompany research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Synthego is a Redwood City, California–based CRISPR solutions company that sells synthetic sgRNAs, nucleases, kits, and GMP-grade genome-engineering reagents and services for life-science research through clinical translation; after a 2025 Chapter 11 sale, it continued operating under Perceptive Advisors ownership.
Primary product
CRISPR genome-engineering reagents, centered on synthetic sgRNA and nuclease products
Founded
2012
Headquarters
3696 Haven Avenue, Suite A, Redwood City, CA 94063, USA
Team size
51-200
Industry
Biotechnology Research
Sub-industry
Genome engineering / CRISPR reagents
Offices
Redwood City, California, United States
Menlo Park, California, United States
Business model
B2B research reagent sales
direct online catalog / e-commerce
Funding
Stage
acquired
Total raised
$472.3M
Latest round
Acquisition (Stalking Horse Asset Sale) · Jul 2025
Latest amount
$85M
Acquisition (Stalking Horse Asset Sale)
Jul 2025 · Perceptive Advisors
May 2025 · Perceptive Credit Holdings III
People & investors
Leadership
President and CEO
Chief Legal Officer
Chief Commercial Officer
Work & culture
Purpose-driven and collaborative, with strong cross-functional teamwork and servant-leadership themes; official messaging emphasizes engineering + scientific excellence and support for employees' well-being.
Visa sponsorship
Yes
Compensation
Public salary signals suggest mid- to high-six-figure pay for senior commercial/technical roles and roughly $105k-$210k for sponsored H-1B positions; public examples include Sr. Research Associate near $125k, QA Specialist near $110k, and Sr. Director, Commercial Development near $210k.
Benefits
Flexible Time Off (FTO)
5 sick days
12 company-paid holidays
12 weeks gender-neutral parental leave
Medical, dental and vision coverage
Product & market
Pricing
Listed-starting-price self-serve pricing for research products, with quote-based enterprise and GMP/custom offerings for larger or regulated programs.
Differentiators
- —Broad CRISPR nuclease compatibility
- —Synthetic sgRNAs with scalable production
- —Research-to-clinic product continuum
- —GMP manufacturing and regulatory support
- —Proprietary automation and bioinformatics
- —High reported editing efficiency on flagship guides
Technology
Canva
Onshape
SolidWorks
Scale & contact
Estimated revenue
$20M-$30M
Estimated monthly visits
87.6K
Traffic estimate as of Jun 2026
Signals & risks
Acquisition
Jul 2025Synthego completed the sale of substantially all assets to funds managed by Perceptive Advisors and said the brand, leadership, and operations would continue.
SourceLatest news
Synthego · Jul 2025
Synthego said the sale of substantially all assets to funds managed by Perceptive Advisors closed on July 18, 2025, and that leadership, staff, brand, and operations would continue under the Synthego name.
Synthego · Jun 2025
The company said its court-supervised sale process had cleared and that the Perceptive transaction was expected to close in July, with the business continuing day to day.
Synthego · May 2025
Synthego announced Chapter 11 restructuring, a purchase agreement with Perceptive Advisors, and up to $2.5 million in DIP financing to keep operations running during the process.
GenomeWeb · Mar 2024
GenomeWeb reported the spinout of Synthego's engineered cell and CRISPR guide RNA business into EditCo Bio, along with a leadership transition.
Open Positions
2 jobs at Synthego
Laboratory Associate II, Pre-Clinical (Swing Shift)
On-siteOperationsRedwood City, CA1w ago
On-site